Anthropic announced the discovery on Wednesday, saying its Claude AI model autonomously identified the system while researchers at the company's recently established biology research laboratory in San Francisco directed it to investigate bacterial DNA sequences.
According to the company, the system has features found in only a small number of known “programmable” biological structures and displays a “pattern reminiscent of CRISPR”, the bacterial defence mechanism that has been adapted by scientists into a powerful tool for editing DNA.
Anthropic said it has not yet determined what the newly identified system actually does. Claude reportedly spent about 21 hours searching a large database of DNA sequences before identifying the unusual molecular structure.
The company’s chief executive, Dario Amodei, said the discovery could potentially represent a new direction in gene editing, while stressing that AI-driven biological discovery remains at an early stage.
In a post on X, Amodei said Anthropic suspected the “molecular machine” could “represent a new gene editing mechanism”. He added that AI was only at the “very beginning” of making discoveries that could eventually contribute to medical breakthroughs.
“I’m genuinely rooting for all of the frontier labs to seriously get into biological discovery, and I’m excited about what comes out of it,” Amodei said.
The announcement has generated excitement among some researchers because of the potential for AI to search enormous biological datasets and identify patterns that could otherwise take scientists considerably longer to find.
Stanley Qi, an associate professor of bioengineering at Stanford University, described the reported discovery as “incredibly exciting”, pointing particularly to the ability of AI to identify unusual biological patterns and investigate them systematically.
“What stands out is its ability to recognize an unusual biological pattern that was difficult to detect before, and to pursue it comprehensively as a research question,” Qi told Al Jazeera.
“Nature contains an enormous diversity of molecular systems we barely understand, and some patterns are very complicated but highly meaningful; AI could greatly expand our ability to explore them more effectively and rapidly, in this case, in just 21 hours,” he added.
However, other scientists have urged caution over comparisons with CRISPR, warning that identifying a CRISPR-like sequence does not mean Anthropic has discovered a new gene-editing technology.
Kevin Blake, a microbiologist at Washington University School of Medicine, said the description of the system as “CRISPR-like” could lead to conclusions that are not yet supported by evidence.
“Because the identified array is ‘CRISPR-like’, some have leaped to conclude Anthropic discovered the ‘next CRISPR’ – ie, a Nobel Prize-winning gene editing technology,” Blake told Al Jazeera.
He noted that CRISPR in nature is fundamentally a bacterial immune system, while CRISPR-based gene editing is the result of scientists adapting that natural mechanism for use in biotechnology.
“CRISPR-the-technology is very different from CRISPR in nature, which is basically a bacterium’s immune system,” Blake said. He added that researchers have long known there are large numbers of CRISPR-like sequences that have yet to be identified, particularly given the enormous number of bacterial species that remain poorly studied.
“There’s nothing to indicate this is a rival to CRISPR-the-technology, or could be developed into any kind of therapeutic or practical application,” he said.
CRISPR-based gene editing has transformed biomedical research and has already contributed to treatments for serious diseases, including sickle cell disease. The technology was pioneered as a gene-editing tool by Emmanuelle Charpentier and Jennifer Doudna, whose work earned them the 2020 Nobel Prize in Chemistry.
The potential medical applications of the technology have continued to expand. Last year, Children’s Hospital of Philadelphia announced that doctors had used a customised CRISPR gene-editing therapy to treat an infant born with carbamoyl phosphate synthetase 1 deficiency, a rare metabolic disorder.
That case was described by the hospital as a “historic” breakthrough and demonstrated the potential of personalised gene-editing treatments.
Anthropic's latest finding, however, remains at an exploratory stage. Before the newly identified bacterial system can be considered a practical gene-editing tool, researchers would need to establish its biological function, determine whether it can be reliably manipulated and assess whether it has any useful or safe applications.
For now, the discovery illustrates a growing role for AI in biological research: rapidly scanning vast amounts of genetic information and flagging molecular patterns that scientists can investigate experimentally.